Effect of supervised training on FEV1 in cystic fibrosis: a randomised controlled trial

Susi Kriemler, Stephanie Kieser, Sibylle Junge, Manfred Ballmann, Alexandra Hebestreit, Christian Schindler, Christoph Stüssi, Helge Hebestreit, Susi Kriemler, Stephanie Kieser, Sibylle Junge, Manfred Ballmann, Alexandra Hebestreit, Christian Schindler, Christoph Stüssi, Helge Hebestreit

Abstract

Background: Long-term exercise interventions have been shown to improve vital capacity in cystic fibrosis (CF). Yet, no data are available indicating positive effects of long-term exercise training on FEV1.

Methods: 39 Swiss patients with CF were randomly divided into strength training (ST, n=12), endurance training (AT, n=17) and controls (CON(CH), n=10), and also compared with age-matched Swiss (n=35) and German (n=701) CF registry data. A partially supervised training of 3×30 min/week for 6 months took place with measurements at baseline and after 3, 6, 12 and 24 months. Primary outcome was FEV1 at 6 months.

Results: FEV1 increased significantly in both training groups compared with CON(CH) (AT:+5.8±0.95, ST:+7.4±2.5, CON(CH):-11.5±2.7% predicted, p<0.001) and both registry groups at 6 months. At 24 months, changes in favour of the training groups persisted marginally compared with CONCH, but not compared with registry data.

Conclusions: A partially supervised training over 6 months improved FEV1 but effects were basically gone 18 months off training. Regular long-term training should be promoted as essential part of treatment in CF.

Trial registration: ClinicalTrials.gov NCT00231686.

Keywords: AT; Aerobic training; CF; CON(CH); CON(D); Control group Germany; Control group Switzerland; Cystic fibrosis; Exercise capacity; FEV(1); FVC; Forced expiratory volume in one second; Forced vital capacity; Lung function; Maximal oxygen consumption at peak endurance; Maximal watt performance; Physical activity; Pulmonary rehabilitation; RV/TLC; Residual volume over total lung capacity; ST; Strength training; VO2(peak); VPA; Vigorous physical activity; W(max).

Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Source: PubMed

3
Tilaa